ABPI statement on Government's Cumberlege Review response

The Government has published its full response to the Cumberlege Review on the safety of medicines and medical devices. 

We are committed to working with the Government to explore how to expand and reinforce our existing platform and to drive continuous improvements in healthcare, based on the experience of patients Richard Torbett

In response, ABPI Chief Executive Richard Torbett said: 

“The pharmaceutical industry is committed to transparency of the work between the medical community and companies.

“Our Disclosure UK platform – an open register of the payments made by companies to healthcare professionals – is leading the way. Disclosure of payments to healthcare professionals via this platform is already mandatory for companies in ABPI membership and those signed up to our Code.

“We are committed to working with the Government to explore how to expand and reinforce our existing platform and to drive continuous improvements in healthcare, based on the experience of patients”.

 

 

 

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.